Résultats de recherche - Portail des modèles médicaux de données (portail MDM)

EBMT Amyloidosis

- 20/09/2021 - 1 Formulaire, 21 Groupes Item, 284 Eléments de données, 1 Langue

Groupes Item: GENERAL INFORMATION TEAM, GENERAL INFORMATION PATIENT, DISEASE, AL AMYLOIDOSIS INITIAL DIAGNOSIS, ORGAN INVOLVEMENT AT DIAGNOSIS, PRE-HSCT TREATMENT, HSCT, STATUS OF DISEASE AT COLLECTION (AUTOGRAFTS ONLY), STATUS OF DISEASE AT START OF CONDITIONING FOR BMT, STATUS OF DISEASE AT 100 DAYS AFTER HSCT, ORGAN-SPECIFIC RESPONSES AT 100 DAYS AFTER HSCT, FORMS TO BE FILLED IN, FOLLOW UP AL AMYLOIDOSIS, PATIENT LAST SEEN, GRAFT VERSUS HOST DISEASE (GvHD) SINCE LAST REPORT, OTHER COMPLICATIONS SINCE LAST REPORT, GRAFT ASSESSMENT AND HAEMOPOIETIC CHIMAERISM, ADDITIONAL THERAPIES SINCE LAST FOLLOW UP, FIRST EVIDENCE OF DISEASE WORSENING SINCE LAST HSCT, LAST DISEASE AND PATIENT STATUS, ADDITIONAL NOTES IF APPLICABLE

ODM form derived from Amyloidosis EBMT refer to: http://www.ebmt.org/Contents/Data-Management/Registrystructure/MED-ABdatacollectionforms/Pages/MED-AB-data-collection-forms.aspx

Treatment - 2450 - Post-Transplant Essential Data (TED) ISO Date Format Version 1 - 2888418v1.0 - 2450 - Post-Transplant Essential Data (TED) ISO Date Format Version 1

- 17/09/2021 - 1 Formulaire, 19 Groupes Item, 107 Eléments de données, 1 Langue

Groupes Item: Registry Use Only, Center Identification, Recipient Identification, 100 Day Report Only, Initial ANC Recovery, Initial Platelet Recovery, Graft versus Host Disease, New Malignancy, Lymphoproliferative or Myeloproliferative Disorder - Part 1 of 2, New Malignancy, Lymphoproliferative or Myeloproliferative Disorder - Part 2 of 2, Survival (Part 1 of 2), Survival (Part 2 of 2), Post - HSCT Therapy, HSCT for Non-Malignant Disease ONLY, Malignant Disease Evaluation for This HSCT, First Relapse or Progression After HSCT, Additional Treatment, Method of Latest Disease Assessment, Donor Cellular Infusion (DCI) (Part 1 of 2), Donor Cellular Infusion (DCI) (Part 2 of 2)

Post-Transplant Essential Data (TED) Uses The ISO Date Format Version 1 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6ABDA2AA-191F-5CB2-E040-BB89AD431CF3

Treatment - 2450 Revision 2 - Post-Transplant Essential Data (TED) - 2898108v1.0 - 2450 Revision 2 - Post-Transplant Essential Data (TED)

- 17/09/2021 - 1 Formulaire, 20 Groupes Item, 109 Eléments de données, 1 Langue

Groupes Item: Registry Use Only, Center Identification, Recipient Identification, 100 Day Report Only, Initial ANC Recovery, Initial Platelet Recovery, Graft versus Host Disease, New Malignancy, Lymphoproliferative or Myeloproliferative Disorder - Part 1 of 3, New Malignancy, Lymphoproliferative or Myeloproliferative Disorder - Part 2 of 3, New Malignancy, Lymphoproliferative or Myeloproliferative Disorder Part 3 of 3, Survival (Part 1 of 2), Survival (Part 2 of 2), Post - HSCT Therapy, HSCT for Non-Malignant Disease ONLY, Malignant Disease Evaluation for This HSCT, First Relapse or Progression After HSCT, Additional Treatment, Method of Latest Disease Assessment, Donor Cellular Infusion (DCI) (Part 1 of 2), Donor Cellular Infusion (DCI) (Part 2 of 2)

Revision 2 of Form 2450 Post-Transplant Essential Data (TED) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6B9E8DCD-3CAF-40FC-E040-BB89AD434581

Treatment - 2450 - Post-Transplant Essential Data (TED) - 2792764v3.0 - 2450 - Post-Transplant Essential Data (TED)

- 17/09/2021 - 1 Formulaire, 19 Groupes Item, 107 Eléments de données, 1 Langue

Groupes Item: Registry Use Only, Center Identification, Recipient Identification, 100 Day Report Only, Initial ANC Recovery, Initial Platelet Recovery, Graft versus Host Disease, New Malignancy, Lymphoproliferative or Myeloproliferative Disorder - Part 1 of 2, New Malignancy, Lymphoproliferative or Myeloproliferative Disorder - Part 2 of 2, Survival (Part 1 of 2), Survival (Part 2 of 2), Post - HSCT Therapy, HSCT for Non-Malignant Disease ONLY, Malignant Disease Evaluation for This HSCT, First Relapse or Progression After HSCT, Additional Treatment, Method of Latest Disease Assessment, Donor Cellular Infusion (DCI) (Part 1 of 2), Donor Cellular Infusion (DCI) (Part 2 of 2)

Post-Transplant Essential Data (TED) Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=60000F98-92BB-426C-E040-BB89AD43447C

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients - Solid organ transplant sub-cohort

- 11/05/2021 - 1 Formulaire, 6 Groupes Item, 31 Eléments de données, 1 Langue

Groupes Item: Type of functioning organ transplant, Most recent transplantation, Immunsuppression at diagnosis of SARS-CoV-2, Graft status before COVID-19, Therapeutic measures of transplant specific therapy, Is data entry for this section finished?

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. This document is for the solid organ transplant sub-cohort. All questions refer to the day of diagnosis (diagnosis means first positive virus result). Please note that only cases with known outcome are collected at LEOSS!